STOCK TITAN

Ispecimen Inc. - ISPC STOCK NEWS

Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.

Company Overview

iSpecimen Inc. (NASDAQ: ISPC) is a dynamic, technology-driven company headquartered in Lexington, MA, that operates a global online marketplace for human biospecimens. Utilizing advanced, proprietary cloud-based technology, iSpecimen connects life science researchers with a comprehensive network of healthcare organizations—including hospitals, laboratories, biobanks, blood centers, and more—to source the specimens needed for critical biomedical research. By providing a streamlined, intuitive search tool, the company enables researchers to efficiently locate biospecimens such as human biofluids, solid tissues, and hematopoietic stem cells, thereby accelerating research discoveries in areas including oncology, immunology, and infectious diseases.

Operational Model and Technological Innovation

At its core, iSpecimen operates as a digital marketplace that overcomes traditional barriers in biospecimen procurement. The platform facilitates seamless transactions between specimen suppliers and scientists. Its robust, cloud-based system allows for intuitive search and data integration across a federated network of healthcare providers, ensuring that researchers gain compliant access to critical specimens within optimized timeframes. This integration is central to the company's ability to shorten fulfillment timelines, as demonstrated by features like the Next Day Quote program, which enables suppliers to provide rapid, accurate pricing and availability to customers.

Core Business Areas and Market Position

iSpecimen is fundamentally positioned at the intersection of healthcare and technology. Its primary business involves sourcing and delivering high-quality human biospecimens for clinical and research purposes. The marketplace supports a diverse range of research disciplines, including cancer research, where the platform offers access to specific oncology biospecimens such as cancer tissue samples from various tumor types. By enabling precise searches based on patient demographics, tumor categorization, and specimen quality, iSpecimen plays a pivotal role in supporting personalized medicine, diagnostics development, and therapeutic innovation.

Revenue Generation and Strategic Partnerships

The company generates revenue primarily by facilitating specimen procurement transactions. Healthcare providers contribute specimens to the marketplace, while researchers access the inventory via a fee-based model that ensures both parties benefit. This symbiotic relationship is enhanced through strategic partnerships, which extend the company’s network globally. Collaborations with major healthcare institutions and specialized cancer centers enhance the diversity and availability of specimens. Furthermore, data-driven strategies in lead generation and supplier capability documentation ensure timely and competitively priced quotes, further supporting the company’s operational efficiency and profitability.

Competitive Landscape and Differentiators

Within the competitive biospecimen market, iSpecimen distinguishes itself by emphasizing technology, compliance, and operational speed. Unlike traditional specimen sourcing methods, its online platform provides a centralized, transparent, and compliant ecosystem. The use of proprietary search tools and rapid quote programs not only accelerates the procurement process but also helps address one of the key challenges in the field—minimizing lead times to support ongoing research. This combination of robust technology, regulatory compliance, and deep industry insight sets iSpecimen apart from competitors, establishing it as an authoritative resource in biomedical research support.

Global Reach and Network Expansion

iSpecimen has cultivated an extensive global network encompassing multiple regions, including the Americas, Europe, Asia Pacific, the Middle East, and Africa. The platform’s international scope ensures that researchers can source high-quality biospecimens from a wide variety of demographic and clinical backgrounds, thus supporting studies that require diverse population samples. This global presence further underscores the company’s commitment to enabling advancements in medical research by ensuring that high-quality, clinically relevant biospecimens are available to researchers regardless of geographical limitations.

Commitment to Compliance and Quality

Critical to the company’s operation is its unwavering commitment to regulatory compliance and specimen quality. iSpecimen’s platform integrates rigorous compliance protocols that ensure all interactions between suppliers and researchers adhere to the highest ethical and operational standards. By maintaining strict data privacy measures and quality control processes, the company builds trust and ensures that both suppliers and customers meet their obligations in the competitive and highly regulated biotech market. This approach not only supports scientific innovation but also fosters a secure and trustworthy environment for specimen exchange.

Impact on Medical Research

By bridging the gap between healthcare organizations and research institutions, iSpecimen significantly impacts medical research. Its platform allows for rapid access to essential biospecimens, which in turn accelerates the pace of discovery in areas such as cancer therapy, personalized medicine, and the study of infectious diseases. Researchers benefit from immediate access to a wide array of biospecimens, enabling precise scientific inquiry and the development of novel diagnostic tools and treatments. The company’s efforts to optimize specimen discovery and procurement are instrumental in driving forward medical innovation and improving global healthcare outcomes.

Summary

In summary, iSpecimen Inc. serves as a technological conduit in the biomedical research ecosystem, providing a robust, user-friendly marketplace that connects life science researchers and healthcare providers. Its innovative platform, strategic global partnerships, and commitment to quality and compliance collectively enable advancements in medical research while ensuring operational efficiency. Whether supporting oncology research with specific cancer biospecimens or responding to emerging research needs, iSpecimen remains a critical component in facilitating groundbreaking scientific discoveries through enhanced biospecimen access.

Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) announced the expansion of its global biospecimen provider network to support research on neurological disorders, affecting approximately one billion people worldwide. Over the past ten months, it has added over a dozen sample providers, supplying biospecimens such as cerebrospinal fluid and other biofluids. iSpecimen can now provide samples from COVID-19 patients exhibiting neurological symptoms, assisting researchers facing biospecimen shortages. This initiative follows National Epilepsy and Alzheimer’s Awareness Months, aiming to facilitate medical discoveries related to these conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.2%
Tags
none
-
Rhea-AI Summary

iSpecimen Inc. (Nasdaq: ISPC) has successfully closed a private placement, raising approximately $21 million by selling 1,749,999 shares of common stock and warrants to purchase 1,312,500 shares. Each share was sold at a price of $12.00, accompanied by three-quarters of a warrant, which has an exercise price of $13.00 and a term of five and a half years. The private placement was managed by ThinkEquity. The securities offered will not be registered under the Securities Act, and iSpecimen plans to file a registration statement with the SEC for resale purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.2%
Tags
none
-
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) has announced a definitive agreement for a private placement to sell 1,749,999 shares of common stock and warrants, expecting to raise approximately $21.0 million in gross proceeds. Each share is priced at $12.00, accompanied by warrants exercisable at $13.00 per share. The placement is set to close on December 1, 2021, subject to customary conditions. The securities will not be registered under the Securities Act and will require a registration statement for resale. This transaction aims to strengthen the company's liquidity and financial position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.62%
Tags
none
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC), a marketplace for human biospecimens, has secured contracts to support advanced COVID-19 research focusing on transmissibility and variant outcomes. The company has partnered with various research organizations over the past ten months, providing samples like nasal swabs and blood products. Notably, iSpecimen has supplied 600 positive and 100 negative serum samples to the CDC for antibody monitoring. Their work extends to military and private organizations, facilitating custom COVID-19 collections across diverse demographics to aid ongoing studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80.49%
Tags
covid-19
-
Rhea-AI Summary

iSpecimen reported strong financial results for Q3 2021, with revenue increasing by 21% to $2.7 million, driven by expanding sales efforts and a growing user base. The company's nine-month revenue surpassed $8.6 million, a 57% increase compared to 2020. Notably, unique suppliers increased to 197 and registered users in the marketplace grew 30% year-over-year. Despite increasing general and administrative expenses to $1.7 million, the net loss reduced to approximately $1.1 million. iSpecimen aims to broaden its offerings and enhance its technology moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.59%
Tags
-
Rhea-AI Summary

iSpecimen Inc. (Nasdaq: ISPC) announces participation in two virtual conferences in November 2021: A.G.P.'s Biotech & Specialty Pharma Conference on November 10 and the 12th Annual Craig-Hallum Alpha Select Conference on November 16. These events will provide opportunities for one-on-one meetings with management. iSpecimen specializes in connecting life scientists to human biospecimens through a unique online marketplace and cloud-based technology, enhancing medical discovery efforts. For more details, visit www.ispecimen.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences
Rhea-AI Summary

iSpecimen Inc. (NASDAQ: ISPC) will announce its third quarter financial results on November 4, 2021, before market open. The conference call is scheduled for 8:30 a.m. ET, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Interested individuals can join the call via toll-free numbers or access a replay until November 18, 2021. The company provides an online marketplace for human biospecimens, connecting scientists with healthcare providers for medical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences
-
Rhea-AI Summary

iSpecimen Inc. (Nasdaq: ISPC) announced an expansion of its human biospecimen supplier network to enhance the availability of whole blood, plasma, and biofluids for liquid biopsy development. This move aims to support a growing market projected to reach $1.45 billion with a 24% annual growth rate through 2026. The company has supplied thousands of biospecimens for nearly 30 studies, reinforcing its commitment to advancing liquid biopsy technology, which offers less invasive disease detection methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
Rhea-AI Summary

iSpecimen Inc. (Nasdaq: ISPC) announced its inclusion in the Russell Microcap Index, effective September 20, 2021. This inclusion signifies recognition of the company's growth in the biospecimen procurement sector, expected to enhance visibility within the investment community. Being part of the Russell indexes, which benchmark approximately $10.6 trillion in assets, positions iSpecimen favorably for attracting institutional investors. The company is also refining its iSpecimen Marketplace, aiming to support researchers in scientific discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC), a leader in the online marketplace for human biospecimens, announced CEO Christopher Ianelli will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. His presentation will be available on-demand starting September 13 at 7:00 a.m. ET. iSpecimen connects life scientists with healthcare providers through its innovative platform to facilitate medical discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
conferences

FAQ

What is the current stock price of Ispecimen (ISPC)?

The current stock price of Ispecimen (ISPC) is $1.31 as of April 1, 2025.

What is the market cap of Ispecimen (ISPC)?

The market cap of Ispecimen (ISPC) is approximately 1.2M.

What does iSpecimen Inc. do?

iSpecimen Inc. operates an online marketplace that connects researchers with healthcare organizations to procure high-quality human biospecimens needed for biomedical research.

How does the iSpecimen platform facilitate research?

The platform uses proprietary, cloud-based technology to allow researchers to search and access biospecimens from a federated network of hospitals, labs, and biobanks, ensuring compliance and rapid turnaround.

What types of biospecimens are available through iSpecimen?

The marketplace provides a range of biospecimens including human biofluids, solid tissues, hematopoietic stem cells, and specialized oncology samples, catering to diverse research needs.

How does iSpecimen generate revenue?

iSpecimen generates revenue by facilitating transactions between healthcare specimen providers and researchers, leveraging a fee-based model and rapid procurement solutions.

What sets iSpecimen apart from traditional specimen sourcing?

By utilizing a digital, cloud-based platform and features like rapid quote generation, iSpecimen streamlines the specimen procurement process, reduces lead times, and ensures regulatory compliance.

What is the significance of the Next Day Quote program?

The Next Day Quote program enables researchers and providers to receive fast and accurate pricing information, significantly accelerating the biospecimen procurement process and enhancing customer satisfaction.

How extensive is iSpecimen's global network?

iSpecimen has established a broad network of healthcare organizations and laboratories across the Americas, Europe, Asia Pacific, the Middle East, and Africa, which supports diverse and high-quality specimen acquisition.

How does iSpecimen ensure specimen quality and compliance?

The company implements rigorous compliance protocols and quality control measures across its platform, ensuring that all biospecimens meet strict ethical and operational standards.
Ispecimen Inc.

Nasdaq:ISPC

ISPC Rankings

ISPC Stock Data

1.21M
823.02k
14.5%
3.71%
12.37%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
WOBURN